Yousif Capital Management LLC Lowers Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Yousif Capital Management LLC cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,232 shares of the medical equipment provider’s stock after selling 1,191 shares during the quarter. Yousif Capital Management LLC’s holdings in Lantheus were worth $2,257,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Signaturefd LLC grew its holdings in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the period. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 146 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Lantheus during the 3rd quarter valued at approximately $25,000. Finally, CWM LLC raised its stake in Lantheus by 63.0% during the third quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 290 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LNTH has been the subject of several analyst reports. The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $131.86.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.50% of the company’s stock.

Lantheus Stock Down 2.0 %

Shares of Lantheus stock opened at $86.91 on Tuesday. Lantheus Holdings, Inc. has a twelve month low of $54.69 and a twelve month high of $126.89. The company’s 50 day moving average is $92.02 and its 200 day moving average is $98.46. The company has a market cap of $6.04 billion, a price-to-earnings ratio of 14.46 and a beta of 0.44.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.